{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T17:19:54Z","timestamp":1794503994426,"version":"4.9.1"},"reference-count":275,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72374119"],"award-info":[{"award-number":["72374119"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02606-7","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:57:41Z","timestamp":1778493461000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The evolving global landscape of first-in-class oncology drug innovation"],"prefix":"10.1038","volume":"11","author":[{"given":"Xiangyun","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0153-8286","authenticated-orcid":false,"given":"Nancy A.","family":"Dreyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0255-4376","authenticated-orcid":false,"given":"Yi","family":"Ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Lotze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1731-938X","authenticated-orcid":false,"given":"Qimin","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3626-7220","authenticated-orcid":false,"given":"Guanqiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"2606_CR1","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1021\/acs.jmedchem.0c01516","volume":"64","author":"DG Brown","year":"2021","unstructured":"Brown, D. G. & Wobst, H. J. A decade of FDA-approved drugs (2010\u20132019): trends and future directions. J. Med. Chem. 64, 2312\u20132338 (2021).","journal-title":"J. Med. Chem."},{"key":"2606_CR2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/d41573-024-00011-9","volume":"23","author":"M Baedeker","year":"2024","unstructured":"Baedeker, M., Ringel, M. S. & M\u00f6ller, C. C. 2023 FDA approvals: unprecedented volume at moderate value. Nat. Rev. Drug Discov. 23, 98\u201398 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR3","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s43018-023-00683-z","volume":"4","author":"E Dolgin","year":"2023","unstructured":"Dolgin, E. Cancer drug approvals and setbacks in 2023. Nat. Cancer 4, 1612\u20131614 (2023).","journal-title":"Nat. Cancer"},{"key":"2606_CR4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrd4336","volume":"13","author":"J Eder","year":"2014","unstructured":"Eder, J., Sedrani, R. & Wiesmann, C. The discovery of first-in-class drugs: origins and evolution. Nat. Rev. Drug Discov. 13, 577\u2013587 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2606_CR6","doi-asserted-by":"publisher","first-page":"114742","DOI":"10.1016\/j.ejmech.2022.114742","volume":"243","author":"J Gu","year":"2022","unstructured":"Gu, J., Wu, Q., Zhang, Q., You, Q. & Wang, L. A decade of approved first-in-class small molecule orphan drugs: achievements, challenges and perspectives. Eur. J. Med. Chem. 243, 114742 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"2606_CR7","unstructured":"FDA. Drugs@FDA: FDA-approved drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=006695 (2025)."},{"key":"2606_CR8","first-page":"157","volume":"4","author":"MM Leo","year":"1950","unstructured":"Leo, M. M., Miller, F. R., Rowen, M. J., Bock, G. & Rutzky, J. Treatment of acute leukemia with amethopterin (4-amino, 10-methyl pteroyl glutamic acid). Acta Hematol. 4, 157\u2013167 (1950).","journal-title":"Acta Hematol."},{"key":"2606_CR9","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1056\/NEJM200009283431309","volume":"343","author":"RJ Mayer","year":"2000","unstructured":"Mayer, R. J. Moving beyond fluorouracil for colorectal cancer. N. Engl. J. Med. 343, 963\u2013964 (2000).","journal-title":"N. Engl. J. Med."},{"key":"2606_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nrd773","volume":"1","author":"P Cohen","year":"2002","unstructured":"Cohen, P. Protein kinases \u2014 the major drug targets of the twenty-first century?. Nat. Rev. Drug Discov. 1, 309\u2013315 (2002).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis, C. A. Trastuzumab \u2014 mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39\u201351 (2007).","journal-title":"N. Engl. J. Med."},{"key":"2606_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","volume":"79","author":"LJ Scott","year":"2019","unstructured":"Scott, L. J. Larotrectinib: first global approval. Drugs 79, 201\u2013206 (2019).","journal-title":"Drugs"},{"key":"2606_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","volume":"14","author":"JA Marin-Acevedo","year":"2021","unstructured":"Marin-Acevedo, J. A., Kimbrough, E. O. & Lou, Y. Next generation of immune checkpoint inhibitors and beyond. J. Hematol. Oncol. J. Hematol. Oncol. 14, 45 (2021).","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"2606_CR14","doi-asserted-by":"publisher","first-page":"113365","DOI":"10.1016\/j.intimp.2024.113365","volume":"143","author":"M Arafat Hossain","year":"2024","unstructured":"Arafat Hossain, M. A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int. Immunopharmacol. 143, 113365 (2024).","journal-title":"Int. Immunopharmacol."},{"key":"2606_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2606_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara, N., Hillan, K. J., Gerber, H.-P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391\u2013400 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/1120009X.2023.2300224","volume":"37","author":"SA Desai","year":"2025","unstructured":"Desai, S. A., Patel, V. P., Bhosle, K. P., Nagare, S. D. & Thombare, K. C. The tumor microenvironment: shaping cancer progression and treatment response. J. Chemother. Florence Italy 37, 15\u201344 (2025).","journal-title":"J. Chemother. Florence Italy"},{"key":"2606_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrd3480","volume":"10","author":"DC Swinney","year":"2011","unstructured":"Swinney, D. C. & Anthony, J. How were new medicines discovered?. Nat. Rev. Drug Discov. 10, 507\u2013519 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/d41573-022-00058-6","volume":"21","author":"G Li","year":"2022","unstructured":"Li, G. et al. Evolution of innovative drug R&D in China. Nat. Rev. Drug Discov. 21, 553\u2013554 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR20","unstructured":"IQVIA. Global Oncology Trends 2024: Outlook to 2028. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/global-oncology-trends-2024 (2025)."},{"key":"2606_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","volume":"22","author":"EC Scott","year":"2023","unstructured":"Scott, E. C. et al. Trends in the approval of cancer therapies by the FDA in the twenty-first century. Nat. Rev. Drug Discov. 22, 625\u2013640 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR22","unstructured":"IQVIA. Global Oncology Trends 2023, https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/global-oncology-trends-2023 (2023)."},{"key":"2606_CR23","unstructured":"FDA. Breakthrough Therapy. https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/breakthrough-therapy (2018)."},{"key":"2606_CR24","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1001\/jamainternmed.2020.1097","volume":"180","author":"EY Chen","year":"2020","unstructured":"Chen, E. Y., Haslam, A. & Prasad, V. FDA acceptance of surrogate end points for cancer drug approval: 1992-2019. JAMA Intern. Med. 180, 912 (2020).","journal-title":"JAMA Intern. Med."},{"key":"2606_CR25","unstructured":"Ministry of Health, and Welfare of Japan. Strategy of SAKIGAKE. https:\/\/www.mhlw.go.jp\/english\/policy\/health-medical\/pharmaceuticals\/140729-01.html (2014)."},{"key":"2606_CR26","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1016\/j.apsb.2022.08.004","volume":"12","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Evolution of drug regulations and regulatory innovation for anticancer drugs in China. Acta Pharm. Sin. B 12, 4365\u20134377 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"2606_CR27","unstructured":"National Medical Products Administration. The Announcement on Three Documents Including the Working Procedures for Review of Breakthrough Therapy Drugs (No. 82 of 2020). https:\/\/www.nmpa.gov.cn\/xxgk\/fgwj\/xzhgfxwj\/20200708151701834.html (2020)."},{"key":"2606_CR28","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/d41573-024-00120-5","volume":"23","author":"Z Chen","year":"2024","unstructured":"Chen, Z. et al. Chinese innovative drug R&D trends in 2024. Nat. Rev. Drug Discov. 23, 810\u2013811 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR29","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.cell.2024.02.040","volume":"187","author":"F Wang","year":"2024","unstructured":"Wang, F., Ruan, D.-Y. & Xu, R.-H. Challenges and opportunities in oncology drug development and clinical research in China. Cell 187, 1578\u20131583 (2024).","journal-title":"Cell"},{"key":"2606_CR30","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1248\/bpb.b22-00868","volume":"46","author":"Y Hino","year":"2023","unstructured":"Hino, Y. et al. Regional disparity in first-in-class anticancer drug development in the US, EU, and Japan. Biol. Pharm. Bull. 46, 700\u2013706 (2023).","journal-title":"Biol. Pharm. Bull."},{"key":"2606_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","volume":"19","author":"L Kraehenbuehl","year":"2022","unstructured":"Kraehenbuehl, L. et al. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat. Rev. Clin. Oncol. 19, 37\u201350 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2606_CR32","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s40265-014-0314-5","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole, R. M. Pembrolizumab: first global approval. Drugs 74, 1973\u20131981 (2014).","journal-title":"Drugs"},{"key":"2606_CR33","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/d41573-022-00030-4","volume":"21","author":"S Upadhaya","year":"2022","unstructured":"Upadhaya, S., Neftelinov, S. T., Hodge, J. & Campbell, J. Challenges and opportunities in the PD1\/PDL1 inhibitor clinical trial landscape. Nat. Rev. Drug Discov. 21, 482\u2013483 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR34","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord, C. J. & Ashworth, A. PARP inhibitors: synthetic lethality in the clinic. Science 355, 1152\u20131158 (2017).","journal-title":"Science"},{"key":"2606_CR35","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1001\/jamaoncol.2023.7322","volume":"10","author":"S Morganti","year":"2024","unstructured":"Morganti, S. et al. PARP inhibitors for breast cancer treatment: a review. JAMA Oncol. 10, 658\u2013670 (2024).","journal-title":"JAMA Oncol."},{"key":"2606_CR36","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DAE Cross","year":"2014","unstructured":"Cross, D. A. E. et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4, 1046\u20131061 (2014).","journal-title":"Cancer Discov."},{"key":"2606_CR37","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1200\/JCO.23.00562","volume":"41","author":"ML Wang","year":"2023","unstructured":"Wang, M. L. et al. Pirtobrutinib in covalent bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J. Clin. Oncol. 41, 3988\u20133997 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2606_CR38","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836\u2013847 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2606_CR39","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.7150\/thno.81494","volume":"13","author":"A Tapia-Galisteo","year":"2023","unstructured":"Tapia-Galisteo, A., Compte, M., \u00c1lvarez-Vallina, L. & Sanz, L. When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy. Theranostics 13, 1028 (2023).","journal-title":"Theranostics"},{"key":"2606_CR40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain, S. M., Shastry, M. & Hamilton, E. Targeting HER2-positive breast cancer: advances and future directions. Nat. Rev. Drug Discov. 22, 101\u2013126 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR41","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40265-025-02163-3","volume":"85","author":"SJ Keam","year":"2025","unstructured":"Keam, S. J. Zanidatamab: first approval. Drugs 85, 707\u2013714 (2025).","journal-title":"Drugs"},{"key":"2606_CR42","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s40265-025-02155-3","volume":"85","author":"HA Blair","year":"2025","unstructured":"Blair, H. A. Zenocutuzumab: first approval. Drugs 85, 591\u2013597 (2025).","journal-title":"Drugs"},{"key":"2606_CR43","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s40265-019-01177-y","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama, Z. T. & Keam, S. J. Entrectinib: first global approval. Drugs 79, 1477\u20131483 (2019).","journal-title":"Drugs"},{"key":"2606_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/d41573-020-00195-w","volume":"20","author":"G Li","year":"2021","unstructured":"Li, G., Qin, Y., Xie, C., Wu, Y.-L. & Chen, X. Trends in oncology drug innovation in China. Nat. Rev. Drug Discov. 20, 15\u201316 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/cancers14010087","volume":"14","author":"A Sochacka-\u0106wik\u0142a","year":"2022","unstructured":"Sochacka-\u0106wik\u0142a, A., M\u0105czy\u0144ski, M. & Regiec, A. FDA-approved drugs for hematological malignancies\u2014the last decade review. Cancers 14, 87 (2022).","journal-title":"Cancers"},{"key":"2606_CR46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.exphem.2018.02.002","volume":"61","author":"J Mihalyova","year":"2018","unstructured":"Mihalyova, J. et al. Venetoclax: a new wave in hematooncology. Exp. Hematol. 61, 10\u201325 (2018).","journal-title":"Exp. Hematol."},{"key":"2606_CR47","unstructured":"FDA. FDA approves gilteritinib for relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. https:\/\/www.fda.gov\/drugs\/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutation (2024)."},{"key":"2606_CR48","first-page":"357027","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal, N. & Iqbal, N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother. Res. Pract. 2014, 357027 (2014).","journal-title":"Chemother. Res. Pract."},{"key":"2606_CR49","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2606_CR50","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2606_CR51","unstructured":"FDA. Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/hematologic-malignancies-regulatory-considerations-use-minimal-residual-disease-development-drug-and (2020)."},{"key":"2606_CR52","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424\u2013447 (2017).","journal-title":"Blood"},{"key":"2606_CR53","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/jha2.759","volume":"4","author":"PG Richardson","year":"2023","unstructured":"Richardson, P. G. et al. Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial. EJHaem 4, 995\u20131005 (2023).","journal-title":"EJHaem"},{"key":"2606_CR54","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca. Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"Ca. Cancer J. Clin."},{"key":"2606_CR55","first-page":"100801","volume":"6","author":"D Zhai","year":"2025","unstructured":"Zhai, D., Zhang, Q., Lu, X., You, Q. & Wang, L. Global first-in-class drugs approved in 2023\u20132024: breakthroughs and insights. Innovation 6, 100801 (2025).","journal-title":"Innovation"},{"key":"2606_CR56","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","volume":"12","author":"M Chevallier","year":"2021","unstructured":"Chevallier, M., Borgeaud, M., Addeo, A. & Friedlaender, A. Oncogenic driver mutations in non-small cell lung cancer: past, present and future. World J. Clin. Oncol. 12, 217\u2013237 (2021).","journal-title":"World J. Clin. Oncol."},{"key":"2606_CR57","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.path.2021.05.009","volume":"14","author":"DS Ross","year":"2021","unstructured":"Ross, D. S. & Pareja, F. Molecular pathology of breast tumors: diagnostic and actionable genetic alterations. Surg. Pathol. Clin. 14, 455\u2013471 (2021).","journal-title":"Surg. Pathol. Clin."},{"key":"2606_CR58","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"D-Y Oh","year":"2020","unstructured":"Oh, D.-Y. & Bang, Y.-J. HER2-targeted therapies \u2014 a role beyond breast cancer. Nat. Rev. Clin. Oncol. 17, 33\u201348 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2606_CR59","doi-asserted-by":"publisher","first-page":"11110","DOI":"10.3390\/ijms241311110","volume":"24","author":"SMB Rodriguez","year":"2023","unstructured":"Rodriguez, S. M. B. et al. An overview of EGFR mechanisms and their implications in targeted therapies for glioblastoma. Int. J. Mol. Sci. 24, 11110 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2606_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01102-1","volume":"14","author":"E Fountzilas","year":"2022","unstructured":"Fountzilas, E., Tsimberidou, A. M., Vo, H. H. & Kurzrock, R. Clinical trial design in the era of precision medicine. Genome Med. 14, 101 (2022).","journal-title":"Genome Med."},{"key":"2606_CR61","doi-asserted-by":"publisher","first-page":"748674","DOI":"10.3389\/fphar.2022.748674","volume":"13","author":"B Ning","year":"2022","unstructured":"Ning, B. et al. The predictive value of tumor mutation burden on clinical efficacy of immune checkpoint inhibitors in melanoma: a systematic review and meta-analysis. Front. Pharmacol. 13, 748674 (2022).","journal-title":"Front. Pharmacol."},{"key":"2606_CR62","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1158\/2326-6066.CIR-20-0983","volume":"9","author":"FS Hodi","year":"2021","unstructured":"Hodi, F. S. et al. TMB and inflammatory gene expression associated with clinical outcomes following immunotherapy in advanced melanoma. Cancer Immunol. Res. 9, 1202\u20131213 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"2606_CR63","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ejso.2016.07.145","volume":"43","author":"C Franklin","year":"2017","unstructured":"Franklin, C., Livingstone, E., Roesch, A., Schilling, B. & Schadendorf, D. Immunotherapy in melanoma: recent advances and future directions. Eur. J. Surg. Oncol. EJSO 43, 604\u2013611 (2017).","journal-title":"Eur. J. Surg. Oncol. EJSO"},{"key":"2606_CR64","unstructured":"Cancer Research Institute. Keytruda Receives 40th FDA Approval. Cancer Research Institute, https:\/\/www.cancerresearch.org\/blog\/june-2024\/keytruda-receives-40th-fda-approval (2024)."},{"key":"2606_CR65","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/d41573-025-00001-5","volume":"24","author":"A Mullard","year":"2025","unstructured":"Mullard, A. 2024 FDA approvals. Nat. Rev. Drug Discov. 24, 75\u201382 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR66","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s40265-024-02056-x","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam, S. J. Zolbetuximab: first approval. Drugs 84, 977\u2013983 (2024).","journal-title":"Drugs"},{"key":"2606_CR67","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara, K. et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-esophageal junction adenocarcinoma (SPOTLIGHT): a multicenter, randomized, double-blind, phase 3 trial. Lancet Lond. Engl. 401, 1655\u20131668 (2023).","journal-title":"Lancet Lond. Engl."},{"key":"2606_CR68","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah, M. A. et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat. Med. 29, 2133\u20132141 (2023).","journal-title":"Nat. Med."},{"key":"2606_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00385-1","volume":"10","author":"W Cao","year":"2022","unstructured":"Cao, W. et al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark. Res. 10, 38 (2022).","journal-title":"Biomark. Res."},{"key":"2606_CR70","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00428-011-1092-z","volume":"459","author":"A Shinozaki","year":"2011","unstructured":"Shinozaki, A. et al. Claudin-18 in biliary neoplasms. Its significance in the classification of intrahepatic cholangiocarcinoma. Virchows Arch. Int. J. Pathol. 459, 73\u201380 (2011).","journal-title":"Virchows Arch. Int. J. Pathol."},{"key":"2606_CR71","doi-asserted-by":"publisher","first-page":"e32882","DOI":"10.1097\/MD.0000000000032882","volume":"102","author":"E Kayikcioglu","year":"2023","unstructured":"Kayikcioglu, E. & Y\u00fcceer, R. O. The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes. Medicine 102, e32882 (2023).","journal-title":"Medicine"},{"key":"2606_CR72","doi-asserted-by":"crossref","unstructured":"Emerging targets in gastric and pancreatic cancer: focus on claudin 18.2. Cancer Lett. 611, 217362 (2025).","DOI":"10.1016\/j.canlet.2024.217362"},{"key":"2606_CR73","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40265-024-02060-1","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam, S. J. Nogapendekin alfa Inbakicept: first approval. Drugs 84, 867\u2013874 (2024).","journal-title":"Drugs"},{"key":"2606_CR74","unstructured":"FDA. FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive nonmuscle invasive bladder cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle-invasive-bladder-cancer (2024)."},{"key":"2606_CR75","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.3390\/cells12121611","volume":"12","author":"G Lui","year":"2023","unstructured":"Lui, G., Minnar, C. M., Soon-Shiong, P., Schlom, J. & Gameiro, S. R. Exploiting an interleukin-15 heterodimeric agonist (N803) for effective immunotherapy of solid malignancies. Cells 12, 1611 (2023).","journal-title":"Cells"},{"key":"2606_CR76","unstructured":"American Association for Cancer Research. First-in-class Immunotherapy Approved for Bladder Cancer. https:\/\/www.aacr.org\/patients-caregivers\/progress-against-cancer\/first-in-class-immunotherapy-approved-for-bladder-cancer\/(2024)."},{"key":"2606_CR77","doi-asserted-by":"publisher","first-page":"5676","DOI":"10.1097\/MS9.0000000000002555","volume":"86","author":"I Alamgir","year":"2024","unstructured":"Alamgir, I. et al. Tarlatamab\u2019s FDA approval: shaping the future of cancer therapy. Ann. Med. Surg. 86, 5676\u20135679 (2024).","journal-title":"Ann. Med. Surg."},{"key":"2606_CR78","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/JCO.22.02823","volume":"41","author":"L Paz-Ares","year":"2023","unstructured":"Paz-Ares, L. et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study. J. Clin. Oncol. 41, 2893\u20132903 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2606_CR79","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.24.00553","volume":"42","author":"A Dowlati","year":"2024","unstructured":"Dowlati, A. et al. Sustained clinical benefit and intracranial activity of tarlatamab in previously treated small cell lung cancer: DeLLphi-300 trial update. J. Clin. Oncol. 42, 3392\u20133399 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2606_CR80","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41571-025-01024-y","volume":"22","author":"RS Herbst","year":"2025","unstructured":"Herbst, R. S. & Chen, L. The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab. Nat. Rev. Clin. Oncol. 22, 461\u2013462 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2606_CR81","doi-asserted-by":"publisher","first-page":"102106","DOI":"10.1016\/j.eclinm.2023.102106","volume":"62","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. et al. AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. EClinicalMedicine 62, 102106 (2023).","journal-title":"EClinicalMedicine"},{"key":"2606_CR82","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.tips.2025.03.002","volume":"46","author":"S Das","year":"2025","unstructured":"Das, S. & Matosevic, S. Afamitresgene autoleucel: first cell therapy for synovial sarcoma. Trends Pharmacol. Sci. 46, 584\u2013585 (2025).","journal-title":"Trends Pharmacol. Sci."},{"key":"2606_CR83","unstructured":"FDA. FDA grants accelerated approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-afamitresgene-autoleucel-unresectable-or-metastatic-synovial-sarcoma (2024)."},{"key":"2606_CR84","doi-asserted-by":"publisher","first-page":"1493346","DOI":"10.3389\/fphar.2025.1493346","volume":"16","author":"W He","year":"2025","unstructured":"He, W. et al. TCR-T-cell therapy for solid tumors: challenges and emerging solutions. Front. Pharmacol. 16, 1493346 (2025).","journal-title":"Front. Pharmacol."},{"key":"2606_CR85","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.3390\/cancers16223776","volume":"16","author":"J Molldrem","year":"2024","unstructured":"Molldrem, J. & Zha, D. Unlocking intracellular oncology targets: the unique role of antibody-based T-cell receptor mimic (TCRm) therapeutics in T-cell engagers (TCEs) and antibody\u2012drug conjugates (ADCs). Cancers 16, 3776 (2024).","journal-title":"Cancers"},{"key":"2606_CR86","unstructured":"FDA. FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation (2024)."},{"key":"2606_CR87","first-page":"3488","volume":"109","author":"MY Salman","year":"2024","unstructured":"Salman, M. Y. & Stein, E. M. Revumenib for patients with acute leukemia: a new tool for differentiation therapy. Hematologica 109, 3488\u20133495 (2024).","journal-title":"Hematologica"},{"key":"2606_CR88","first-page":"1","volume":"10","author":"SV Liu","year":"2025","unstructured":"Liu, S. V., Nagasaka, M., Atz, J., Solca, F. & M\u00fcllauer, L. Oncogenic gene fusions in cancer: from biology to therapy. Signal Transduct. Target. Ther. 10, 1\u201320 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2606_CR89","doi-asserted-by":"crossref","unstructured":"Kim, D.-W. et al. The phase I\/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions. Future Oncol. 20, 1057\u20131067 (2024).","DOI":"10.2217\/fon-2023-0824"},{"key":"2606_CR90","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","volume":"12","author":"GR Zimmermann","year":"2007","unstructured":"Zimmermann, G. R., Leh\u00e1r, J. & Keith, C. T. Multitarget therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 12, 34\u201342 (2007).","journal-title":"Drug Discov. Today"},{"key":"2606_CR91","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.ejmech.2017.10.021","volume":"143","author":"NM Raghavendra","year":"2018","unstructured":"Raghavendra, N. M., Pingili, D., Kadasi, S., Mettu, A. & Prasad, S. V. U. M. Dual or multitargeting inhibitors: the next generation anticancer agents. Eur. J. Med. Chem. 143, 1277\u20131300 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"2606_CR92","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","volume":"32","author":"M Hay","year":"2014","unstructured":"Hay, M., Thomas, D. W., Craighead, J. L., Economides, C. & Rosenthal, J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40\u201351 (2014).","journal-title":"Nat. Biotechnol."},{"key":"2606_CR93","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/d41573-019-00074-z","volume":"18","author":"H Dowden","year":"2019","unstructured":"Dowden, H. & Munro, J. Trends in clinical success rates and therapeutic focus. Nat. Rev. Drug Discov. 18, 495\u2013496 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR94","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nrd.2016.85","volume":"15","author":"K Smietana","year":"2016","unstructured":"Smietana, K., Siatkowski, M. & M\u00f8ller, M. Trends in clinical success rates. Nat. Rev. Drug Discov. 15, 379\u2013380 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR95","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong, C. H., Siah, K. W. & Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics 20, 273\u2013286 (2019).","journal-title":"Biostatistics"},{"key":"2606_CR96","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nrd4309","volume":"13","author":"D Cook","year":"2014","unstructured":"Cook, D. et al. Lessons learned from the fate of AstraZeneca\u2019s drug pipeline: a five-dimensional framework. Nat. Rev. Drug Discov. 13, 419\u2013431 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR97","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","volume":"36","author":"J Groffen","year":"1984","unstructured":"Groffen, J. et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36, 93\u201399 (1984).","journal-title":"Cell"},{"key":"2606_CR98","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien, S. G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994\u20131004 (2003).","journal-title":"N. Engl. J. Med."},{"key":"2606_CR99","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"2606_CR100","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","volume":"136","author":"J Luo","year":"2009","unstructured":"Luo, J., Solimini, N. L. & Elledge, S. J. Principles of cancer therapy: oncogene and nononcogene addiction. Cell 136, 823\u2013837 (2009).","journal-title":"Cell"},{"key":"2606_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/s12918-017-0464-7","volume":"11","author":"J Sun","year":"2017","unstructured":"Sun, J. et al. A systematic analysis of FDA-approved anticancer drugs. BMC Syst. Biol. 11, 87 (2017).","journal-title":"BMC Syst. Biol."},{"key":"2606_CR102","unstructured":"Organization for Economic Co-operation and Development. Access to Oncology Medicines in EU and OECD Countries, Vol. 170 https:\/\/www.oecd.org\/en\/publications\/access-to-oncology-medicines-in-eu-and-oecd-countries_c263c014-en.html (2024)."},{"key":"2606_CR103","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd.2018.21","volume":"17","author":"FM Ferguson","year":"2018","unstructured":"Ferguson, F. M. & Gray, N. S. Kinase inhibitors: the road ahead. Nat. Rev. Drug Discov. 17, 353\u2013377 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR104","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1002\/cncr.34757","volume":"129","author":"M Herrera-Ju\u00e1rez","year":"2023","unstructured":"Herrera-Ju\u00e1rez, M., Serrano-G\u00f3mez, C., Bote-de-Cabo, H. & Paz-Ares, L. Targeted therapy for lung cancer: beyond EGFR and ALK. Cancer 129, 1803\u20131820 (2023).","journal-title":"Cancer"},{"key":"2606_CR105","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.3390\/ijms21134576","volume":"21","author":"AM Czarnecka","year":"2020","unstructured":"Czarnecka, A. M., Bartnik, E., Fiedorowicz, M. & Rutkowski, P. Targeted therapy in melanoma and mechanisms of resistance. Int. J. Mol. Sci. 21, 4576 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2606_CR106","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3390\/cancers15020466","volume":"15","author":"P Sehgal","year":"2023","unstructured":"Sehgal, P. & Chaturvedi, P. Chromatin and cancer: implications of disrupted chromatin organization in tumorigenesis and its diversification. Cancers 15, 466 (2023).","journal-title":"Cancers"},{"key":"2606_CR107","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-017-0081-z","volume":"5","author":"W Zhang","year":"2017","unstructured":"Zhang, W. & Xu, J. DNA methyltransferases and their roles in tumorigenesis. Biomark. Res. 5, 1 (2017).","journal-title":"Biomark. Res."},{"key":"2606_CR108","first-page":"277","volume":"2","author":"Y Yang","year":"2022","unstructured":"Yang, Y., Zhang, M. & Wang, Y. The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy. J. Natl. Cancer Cent. 2, 277\u2013290 (2022).","journal-title":"J. Natl. Cancer Cent."},{"key":"2606_CR109","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1080\/14656566.2023.2272659","volume":"24","author":"A Bruzzese","year":"2023","unstructured":"Bruzzese, A. et al. Ivosidenib in acute myeloid leukemia. Expert Opin. Pharmacother. 24, 2093\u20132100 (2023).","journal-title":"Expert Opin. Pharmacother."},{"key":"2606_CR110","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein, E. M. et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130, 722\u2013731 (2017).","journal-title":"Blood"},{"key":"2606_CR111","doi-asserted-by":"crossref","unstructured":"Julia, E. & Salles, G. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed\/refractory follicular lymphoma. Future Oncol. 17, 2127\u20132140 (2021).","DOI":"10.2217\/fon-2020-1244"},{"key":"2606_CR112","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.biopha.2018.02.067","volume":"101","author":"A Thakur","year":"2018","unstructured":"Thakur, A., Roy, A., Ghosh, A., Chhabra, M. & Banerjee, S. Abiraterone acetate in the treatment of prostate cancer. Biomed. Pharmacother. 101, 211\u2013218 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"2606_CR113","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrd3753","volume":"11","author":"A Dlugosz","year":"2012","unstructured":"Dlugosz, A., Agrawal, S. & Kirkpatrick, P. Vismodegib. Nat. Rev. Drug Discov. 11, 437\u2013438 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR114","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40265-015-0345-6","volume":"75","author":"ED Deeks","year":"2015","unstructured":"Deeks, E. D. Olaparib: first global approval. Drugs 75, 231\u2013240 (2015).","journal-title":"Drugs"},{"key":"2606_CR115","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s40265-019-01188-9","volume":"79","author":"YY Syed","year":"2019","unstructured":"Syed, Y. Y. Selinexor: first global approval. Drugs 79, 1485\u20131494 (2019).","journal-title":"Drugs"},{"key":"2606_CR116","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang, R. et al. Antibody\u2013Drug Conjugates (ADCs): current and future biopharmaceuticals. J. Hematol. Oncol. J. Hematol. Oncol. 18, 51 (2025).","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"2606_CR117","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40265-022-01749-5","volume":"82","author":"C Kang","year":"2022","unstructured":"Kang, C. Mosunetuzumab: first approval. Drugs 82, 1229\u20131234 (2022).","journal-title":"Drugs"},{"key":"2606_CR118","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1007\/s00432-020-03404-6","volume":"146","author":"S Huang","year":"2020","unstructured":"Huang, S., van Duijnhoven, S. M. J., Sijts, A. J. A. M. & van Elsas, A. Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy. J. Cancer Res. Clin. Oncol. 146, 3111\u20133122 (2020).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2606_CR119","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","volume":"17","author":"W Cheng","year":"2024","unstructured":"Cheng, W., Kang, K., Zhao, A. & Wu, Y. Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer. J. Hematol. Oncol. J. Hematol. Oncol. 17, 54 (2024).","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"2606_CR120","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/cancers9050052","volume":"9","author":"P Wee","year":"2017","unstructured":"Wee, P. & Wang, Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers 9, 52 (2017).","journal-title":"Cancers"},{"key":"2606_CR121","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jaccao.2022.09.004","volume":"4","author":"S Tan","year":"2022","unstructured":"Tan, S., Day, D., Nicholls, S. J. & Segelov, E. Immune checkpoint inhibitor therapy in oncology: current uses and future directions. JACC CardioOncol. 4, 579\u2013597 (2022).","journal-title":"JACC CardioOncol."},{"key":"2606_CR122","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/s41418-025-01481-z","volume":"32","author":"CM Croce","year":"2025","unstructured":"Croce, C. M. et al. The BCL-2 protein family: from discovery to drug development. Cell Death Differ. 32, 1369\u20131381 (2025).","journal-title":"Cell Death Differ."},{"key":"2606_CR123","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","volume":"24","author":"Y Drew","year":"2025","unstructured":"Drew, Y., Zenke, F. T. & Curtin, N. J. DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications. Nat. Rev. Drug Discov. 24, 19\u201339 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR124","doi-asserted-by":"crossref","unstructured":"The tumor microenvironment: a key player in multidrug resistance in cancer. Oncologie 26, 41\u201358 (2023).","DOI":"10.1515\/oncologie-2023-0459"},{"key":"2606_CR125","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10555-020-09936-0","volume":"40","author":"C Ruggiero","year":"2021","unstructured":"Ruggiero, C. & Lalli, E. Targeting the cytoskeleton against metastatic dissemination. Cancer Metastasis Rev. 40, 89\u2013140 (2021).","journal-title":"Cancer Metastasis Rev."},{"key":"2606_CR126","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","volume":"131","author":"C Chester","year":"2018","unstructured":"Chester, C., Sanmamed, M. F., Wang, J. & Melero, I. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood 131, 49\u201357 (2018).","journal-title":"Blood"},{"key":"2606_CR127","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.drudis.2020.11.003","volume":"26","author":"W-B Yu","year":"2021","unstructured":"Yu, W.-B., Ye, Z.-H., Chen, X., Shi, J.-J. & Lu, J.-J. The development of small-molecule inhibitors targeting CD47. Drug Discov. Today 26, 561\u2013568 (2021).","journal-title":"Drug Discov. Today"},{"key":"2606_CR128","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3390\/cancers14061550","volume":"14","author":"JR Faust","year":"2022","unstructured":"Faust, J. R., Hamill, D., Kolb, E. A., Gopalakrishnapillai, A. & Barwe, S. P. Mesothelin: an immunotherapeutic target beyond solid tumors. Cancers 14, 1550 (2022).","journal-title":"Cancers"},{"key":"2606_CR129","first-page":"333","volume":"47","author":"M Ho","year":"2011","unstructured":"Ho, M. & Kim, H. Glypican-3: a new target for cancer immunotherapy. Eur. J. Cancer Oxf. Engl. 1990 47, 333\u2013338 (2011).","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"key":"2606_CR130","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/2326-6066.CIR-17-0102","volume":"5","author":"MJ Atherton","year":"2017","unstructured":"Atherton, M. J. et al. Customized Viral Immunotherapy for HPV-Associated Cancer. Cancer Immunol. Res. 5, 847\u2013859 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"2606_CR131","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1053\/j.semnuclmed.2020.05.004","volume":"50","author":"S Basu","year":"2020","unstructured":"Basu, S. et al. Peptide receptor radionuclide therapy of neuroendocrine tumors. Semin. Nucl. Med. 50, 447\u2013464 (2020).","journal-title":"Semin. Nucl. Med."},{"key":"2606_CR132","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371\u20132381 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2606_CR133","unstructured":"FDA. FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer (2024)."},{"key":"2606_CR134","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s40425-019-0777-8","volume":"7","author":"A Berger","year":"2019","unstructured":"Berger, A. et al. Interleukin-15 in cancer immunotherapy: IL-15 receptor complex versus soluble IL-15 in a cancer cell-delivered murine leukemia model. J. Immunother. Cancer 7, 355 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2606_CR135","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/onc.2013.527","volume":"34","author":"S Busch","year":"2015","unstructured":"Busch, S. et al. TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in premenopausal breast cancer. Oncogene 34, 27\u201338 (2015).","journal-title":"Oncogene"},{"key":"2606_CR136","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29309","volume":"95","author":"S Lee","year":"2023","unstructured":"Lee, S. et al. mRNA-HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV-mediated cancers via subcutaneous immunization. J. Med. Virol. 95, e29309 (2023).","journal-title":"J. Med. Virol."},{"key":"2606_CR137","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","volume":"30","author":"A Singhal","year":"2024","unstructured":"Singhal, A., Li, B. T. & O\u2019Reilly, E. M. Targeting KRAS in cancer. Nat. Med. 30, 969\u2013983 (2024).","journal-title":"Nat. Med."},{"key":"2606_CR138","doi-asserted-by":"publisher","first-page":"793121","DOI":"10.3389\/fonc.2021.793121","volume":"11","author":"M Cucurull","year":"2021","unstructured":"Cucurull, M. et al. Targeting KRAS in lung cancer beyond KRAS G12C inhibitors: the immune regulatory role of KRAS and novel therapeutic strategies. Front. Oncol. 11, 793121 (2021).","journal-title":"Front. Oncol."},{"key":"2606_CR139","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/d41573-020-00130-z","volume":"19","author":"A Mullard","year":"2020","unstructured":"Mullard, A. p53 programmes plow on. Nat. Rev. Drug Discov. 19, 497\u2013500 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR140","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1158\/2159-8290.CD-24-1421","volume":"15","author":"AM Puzio-Kuter","year":"2025","unstructured":"Puzio-Kuter, A. M. et al. Restoration of the tumor suppressor function of Y220C-mutant p53 by Rezatapopt, a small-molecule reactivator. Cancer Discov. 15, 1159\u20131179 (2025).","journal-title":"Cancer Discov."},{"key":"2606_CR141","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.semcancer.2020.07.005","volume":"79","author":"MJ Duffy","year":"2022","unstructured":"Duffy, M. J., Synnott, N. C., O\u2019Grady, S. & Crown, J. Targeting p53 for the treatment of cancer. Semin. Cancer Biol. 79, 58\u201367 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"2606_CR142","doi-asserted-by":"publisher","first-page":"eadn6274","DOI":"10.1126\/scitranslmed.adn6274","volume":"17","author":"V Rendo","year":"2025","unstructured":"Rendo, V. et al. Window of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma. Sci. Transl. Med. 17, eadn6274 (2025).","journal-title":"Sci. Transl. Med."},{"key":"2606_CR143","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41375-024-02241-7","volume":"38","author":"HL Bell","year":"2024","unstructured":"Bell, H. L. et al. Combination p53 activation and BCL-xL\/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. Leukemia 38, 1223\u20131235 (2024).","journal-title":"Leukemia"},{"key":"2606_CR144","doi-asserted-by":"crossref","unstructured":"Bukhari, A. B. et al. Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis. J. Clin. Invest. 129, 1329\u20131344 (2019).","DOI":"10.1172\/JCI122622"},{"key":"2606_CR145","doi-asserted-by":"publisher","first-page":"915","DOI":"10.20892\/j.issn.2095-3941.2023.0260","volume":"20","author":"Q Tang","year":"2023","unstructured":"Tang, Q., Wang, X., Wang, H., Zhong, L. & Zou, D. Advances in ATM, ATR, WEE1, and CHK1\/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer. Cancer Biol. Med. 20, 915\u2013921 (2023).","journal-title":"Cancer Biol. Med."},{"key":"2606_CR146","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/med.21942","volume":"43","author":"A Divakaran","year":"2023","unstructured":"Divakaran, A., Harki, D. A. & Pomerantz, W. C. K. Recent progress and structural analyses of domain-selective BET inhibitors. Med. Res. Rev. 43, 972\u20131018 (2023).","journal-title":"Med. Res. Rev."},{"key":"2606_CR147","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067\u20131073 (2010).","journal-title":"Nature"},{"key":"2606_CR148","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1038\/leu.2016.355","volume":"31","author":"KT Siu","year":"2017","unstructured":"Siu, K. T. et al. Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extraterminal protein inhibitor in the therapy of multiple myeloma. Leukemia 31, 1760\u20131769 (2017).","journal-title":"Leukemia"},{"key":"2606_CR149","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.3390\/molecules28073043","volume":"28","author":"KKW To","year":"2023","unstructured":"To, K. K. W., Xing, E., Larue, R. C. & Li, P.-K. BET bromodomain inhibitors: novel design strategies and therapeutic applications. Molecules 28, 3043 (2023).","journal-title":"Molecules"},{"key":"2606_CR150","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.1021\/acs.jmedchem.6b01761","volume":"60","author":"Z Liu","year":"2017","unstructured":"Liu, Z. et al. Drug discovery targeting bromodomain-containing protein 4. J. Med. Chem. 60, 4533\u20134558 (2017).","journal-title":"J. Med. Chem."},{"key":"2606_CR151","doi-asserted-by":"publisher","first-page":"11102","DOI":"10.3390\/ijms222011102","volume":"22","author":"J Sarnik","year":"2021","unstructured":"Sarnik, J., Pop\u0142awski, T. & Tokarz, P. BET proteins as attractive targets for cancer therapeutics. Int. J. Mol. Sci. 22, 11102 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2606_CR152","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41421-023-00544-0","volume":"9","author":"Y Shi","year":"2023","unstructured":"Shi, Y. et al. BRD4-targeting PROTAC as a unique tool to study biomolecular condensates. Cell Discov. 9, 47 (2023).","journal-title":"Cell Discov."},{"key":"2606_CR153","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","volume":"348","author":"GE Winter","year":"2015","unstructured":"Winter, G. E. et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376\u20131381 (2015).","journal-title":"Science"},{"key":"2606_CR154","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","volume":"22","author":"J Lu","year":"2015","unstructured":"Lu, J. et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22, 755\u2013763 (2015).","journal-title":"Chem. Biol."},{"key":"2606_CR155","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","volume":"8","author":"Z-Q Wang","year":"2023","unstructured":"Wang, Z.-Q. et al. Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy. Signal Transduct. Target. Ther. 8, 420 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2606_CR156","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41420-024-02112-1","volume":"10","author":"R Gadet","year":"2024","unstructured":"Gadet, R. et al. The endoplasmic reticulum pool of Bcl-xL prevents cell death through IP3R-dependent calcium release. Cell Death Discov. 10, 346 (2024).","journal-title":"Cell Death Discov."},{"key":"2606_CR157","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60238-x","volume":"16","author":"A Varkaris","year":"2025","unstructured":"Varkaris, A. et al. BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress. Nat. Commun. 16, 4931 (2025).","journal-title":"Nat. Commun."},{"key":"2606_CR158","doi-asserted-by":"publisher","first-page":"104547","DOI":"10.1016\/j.phrs.2019.104547","volume":"151","author":"M Li","year":"2020","unstructured":"Li, M., Wang, D., He, J., Chen, L. & Li, H. Bcl-XL: a multifunctional anti-apoptotic protein. Pharmacol. Res. 151, 104547 (2020).","journal-title":"Pharmacol. Res."},{"key":"2606_CR159","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421\u20133428 (2008).","journal-title":"Cancer Res."},{"key":"2606_CR160","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","volume":"30","author":"AW Roberts","year":"2012","unstructured":"Roberts, A. W. et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 30, 488\u2013496 (2012).","journal-title":"J. Clin. Oncol."},{"key":"2606_CR161","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","volume":"25","author":"S Khan","year":"2019","unstructured":"Khan, S. et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat. Med. 25, 1938\u20131947 (2019).","journal-title":"Nat. Med."},{"key":"2606_CR162","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","volume":"8","author":"S Caenepeel","year":"2018","unstructured":"Caenepeel, S. et al. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 8, 1582\u20131597 (2018).","journal-title":"Cancer Discov."},{"key":"2606_CR163","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","volume":"10","author":"M Vogler","year":"2025","unstructured":"Vogler, M. et al. The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy. Signal Transduct. Target. Ther. 10, 91 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2606_CR164","doi-asserted-by":"crossref","unstructured":"Llombart, V. & Mansour, M. R. Therapeutic targeting of \u201cundruggable\u201d MYC. eBioMedicine 75, 103756 (2022).","DOI":"10.1016\/j.ebiom.2021.103756"},{"key":"2606_CR165","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41591-024-02805-1","volume":"30","author":"E Garralda","year":"2024","unstructured":"Garralda, E. et al. MYC targeting by OMO-103 in solid tumors: a phase 1 trial. Nat. Med. 30, 762\u2013771 (2024).","journal-title":"Nat. Med."},{"key":"2606_CR166","doi-asserted-by":"publisher","first-page":"205","DOI":"10.20517\/cdr.2022.127","volume":"6","author":"S Mart\u00ednez-Mart\u00edn","year":"2023","unstructured":"Mart\u00ednez-Mart\u00edn, S., Beaulieu, M.-E. & Soucek, L. Targeting MYC-driven lymphoma: lessons learned and future directions. Cancer Drug Resist. 6, 205\u2013222 (2023).","journal-title":"Cancer Drug Resist."},{"key":"2606_CR167","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1002\/hep.31864","volume":"74","author":"Y Luo","year":"2021","unstructured":"Luo, Y. et al. Myelocytomatosis-protein arginine N-methyltransferase 5 axis defines the tumorigenesis and immune response in hepatocellular carcinoma. Hepatol. Baltim. Md 74, 1932\u20131951 (2021).","journal-title":"Hepatol. Baltim. Md"},{"key":"2606_CR168","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01434-3","volume":"21","author":"X Li","year":"2022","unstructured":"Li, X. et al. Proteolysis-targeting chimeras (PROTACs) in cancer therapy. Mol. Cancer 21, 99 (2022).","journal-title":"Mol. Cancer"},{"key":"2606_CR169","doi-asserted-by":"publisher","first-page":"101435","DOI":"10.1016\/j.gendis.2024.101435","volume":"12","author":"Y Duan","year":"2025","unstructured":"Duan, Y. et al. Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology. Genes Dis. 12, 101435 (2025).","journal-title":"Genes Dis."},{"key":"2606_CR170","doi-asserted-by":"publisher","unstructured":"Whitfield, J. R. & Soucek, L. MYC in cancer: from undruggable target to clinical trials. Nat. Rev. Drug Discov. 1\u201313 https:\/\/doi.org\/10.1038\/s41573-025-01143-2 (2025).","DOI":"10.1038\/s41573-025-01143-2"},{"key":"2606_CR171","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1002\/med.21787","volume":"41","author":"Z Wang","year":"2021","unstructured":"Wang, Z., Li, Z. & Ji, H. Direct targeting of \u03b2-catenin in the Wnt signaling pathway: Current progress and perspectives. Med. Res. Rev. 41, 2109\u20132129 (2021).","journal-title":"Med. Res. Rev."},{"key":"2606_CR172","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59309-w","volume":"16","author":"M Yu","year":"2025","unstructured":"Yu, M. et al. The mechanism of YAP\/TAZ transactivation and dual targeting for cancer therapy. Nat. Commun. 16, 3855 (2025).","journal-title":"Nat. Commun."},{"key":"2606_CR173","doi-asserted-by":"publisher","first-page":"114847","DOI":"10.1016\/j.ejmech.2022.114847","volume":"244","author":"M Luo","year":"2022","unstructured":"Luo, M. et al. Advances of targeting the YAP\/TAZ-TEAD complex in the hippo pathway for the treatment of cancers. Eur. J. Med. Chem. 244, 114847 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"2606_CR174","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41392-023-01441-4","volume":"8","author":"G Yin","year":"2023","unstructured":"Yin, G. et al. Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS. Signal Transduct. Target. Ther. 8, 212 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2606_CR175","doi-asserted-by":"publisher","first-page":"672","DOI":"10.18632\/oncotarget.28469","volume":"14","author":"A Tomazini","year":"2023","unstructured":"Tomazini, A. & Shifman, J. M. Targeting Ras with protein engineering. Oncotarget 14, 672\u2013687 (2023).","journal-title":"Oncotarget"},{"key":"2606_CR176","doi-asserted-by":"publisher","first-page":"1280741","DOI":"10.3389\/fimmu.2023.1280741","volume":"14","author":"F Riaz","year":"2023","unstructured":"Riaz, F., Huang, Z. & Pan, F. Targeting posttranslational modifications of Foxp3: a new paradigm for regulatory T-cell-specific therapy. Front. Immunol. 14, 1280741 (2023).","journal-title":"Front. Immunol."},{"key":"2606_CR177","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi, P. F. et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicenter, open-label, single-arm, phase 2 trial. Lancet Oncol. 22, 790\u2013800 (2021).","journal-title":"Lancet Oncol."},{"key":"2606_CR178","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B-cell tumors: a phase 1\/2 trial. Nat. Med. 30, 772\u2013784 (2024).","journal-title":"Nat. Med."},{"key":"2606_CR179","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.semcancer.2019.11.004","volume":"65","author":"S Lesch","year":"2020","unstructured":"Lesch, S. et al. Determinants of response and resistance to CAR T-cell therapy. Semin. Cancer Biol. 65, 80\u201390 (2020).","journal-title":"Semin. Cancer Biol."},{"key":"2606_CR180","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41573-022-00476-6","volume":"21","author":"CJ Bashor","year":"2022","unstructured":"Bashor, C. J., Hilton, I. B., Bandukwala, H., Smith, D. M. & Veiseh, O. Engineering the next generation of cell-based therapeutics. Nat. Rev. Drug Discov. 21, 655\u2013675 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR181","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01518-8","volume":"21","author":"S-W Wang","year":"2022","unstructured":"Wang, S.-W. et al. Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer. Mol. Cancer 21, 57 (2022).","journal-title":"Mol. Cancer"},{"key":"2606_CR182","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020).","journal-title":"Science"},{"key":"2606_CR183","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-92209-z","volume":"15","author":"F Zhao","year":"2025","unstructured":"Zhao, F. et al. Engineered PD-L1 coexpression in PD-1 knockout and MAGE-C2-targeting TCR-T cells augments the cytotoxic efficacy toward target cancer cells. Sci. Rep. 15, 11894 (2025).","journal-title":"Sci. Rep."},{"key":"2606_CR184","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-024-01639-1","volume":"17","author":"H Huang","year":"2024","unstructured":"Huang, H. et al. Advances in CAR-T-cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress. J. Hematol. Oncol. 17, 120 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2606_CR185","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T-cell therapy: what we know thus far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2606_CR186","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/cells13020146","volume":"13","author":"C Lonez","year":"2024","unstructured":"Lonez, C. & Breman, E. Allogeneic CAR-T therapy technologies: has the promise been met?. Cells 13, 146 (2024).","journal-title":"Cells"},{"key":"2606_CR187","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.3390\/cancers14133230","volume":"14","author":"B Xie","year":"2022","unstructured":"Xie, B., Li, Z., Zhou, J. & Wang, W. Current status and perspectives of dual-targeting chimeric antigen receptor T-cell therapy for the treatment of hematological malignancies. Cancers 14, 3230 (2022).","journal-title":"Cancers"},{"key":"2606_CR188","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/s43018-025-01020-2","volume":"6","author":"V Giacco","year":"2025","unstructured":"Giacco, V. Tumor-infiltrating lymphocyte therapies in gastrointestinal cancer. Nat. Cancer 6, 1122\u20131122 (2025).","journal-title":"Nat. Cancer"},{"key":"2606_CR189","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/d41573-023-00206-6","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard, A. Tumor-infiltrating lymphocyte cancer therapy nears FDA finish line. Nat. Rev. Drug Discov. 23, 3\u20137 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR190","first-page":"1","volume":"8","author":"D Lin","year":"2023","unstructured":"Lin, D., Shen, Y. & Liang, T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct. Target. Ther. 8, 1\u201329 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2606_CR191","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-71977-0","volume":"14","author":"Y Chen","year":"2024","unstructured":"Chen, Y., Ren, X., Dai, Y. & Wang, Y. Pharmacovigilance study of the association between peripheral neuropathy and antibody\u2013drug conjugates using the FDA adverse event reporting system. Sci. Rep. 14, 21386 (2024).","journal-title":"Sci. Rep."},{"key":"2606_CR192","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.3390\/ijms25136969","volume":"25","author":"AA Chis","year":"2024","unstructured":"Chis, A. A. et al. Antibody\u2013drug conjugates\u2014evolution and perspectives. Int. J. Mol. Sci. 25, 6969 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2606_CR193","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s42004-025-01491-5","volume":"8","author":"B Parshad","year":"2025","unstructured":"Parshad, B. et al. Toward precision medicine using biochemically triggered cleavable conjugation. Commun. Chem. 8, 100 (2025).","journal-title":"Commun. Chem."},{"key":"2606_CR194","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","volume":"15","author":"S Li","year":"2025","unstructured":"Li, S. et al. Resistance to antibody\u2013drug conjugates: a review. Acta Pharm. Sin. B 15, 737\u2013756 (2025).","journal-title":"Acta Pharm. Sin. B"},{"key":"2606_CR195","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","volume":"200","author":"PK Mahalingaiah","year":"2019","unstructured":"Mahalingaiah, P. K. et al. Potential mechanisms of target-independent uptake and toxicity of antibody\u2012drug conjugates. Pharmacol. Ther. 200, 110\u2013125 (2019).","journal-title":"Pharmacol. Ther."},{"key":"2606_CR196","doi-asserted-by":"publisher","first-page":"15716","DOI":"10.1021\/acs.jmedchem.1c00961","volume":"64","author":"L He","year":"2021","unstructured":"He, L. et al. Immune modulating antibody\u2012drug conjugate (IM-ADC) for cancer immunotherapy. J. Med. Chem. 64, 15716\u201315726 (2021).","journal-title":"J. Med. Chem."},{"key":"2606_CR197","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181\u2013200 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR198","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02024-9","volume":"23","author":"C Wang","year":"2024","unstructured":"Wang, C., Zhang, Y., Chen, W., Wu, Y. & Xing, D. New-generation advanced PROTACs as potential therapeutic agents in cancer therapy. Mol. Cancer 23, 110 (2024).","journal-title":"Mol. Cancer"},{"key":"2606_CR199","doi-asserted-by":"publisher","first-page":"116166","DOI":"10.1016\/j.ejmech.2024.116166","volume":"267","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Annual review of PROTAC degraders as anticancer agents in 2022. Eur. J. Med. Chem. 267, 116166 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"2606_CR200","doi-asserted-by":"publisher","first-page":"9334","DOI":"10.1021\/jacs.3c02619","volume":"145","author":"X Li","year":"2023","unstructured":"Li, X. et al. c-Myc-targeting PROTAC based on a TNA-DNA bivalent binder for combination therapy of triple-negative breast cancer. J. Am. Chem. Soc. 145, 9334\u20139342 (2023).","journal-title":"J. Am. Chem. Soc."},{"key":"2606_CR201","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.tips.2024.07.003","volume":"45","author":"Z Wang","year":"2024","unstructured":"Wang, Z., Liao, X., He, H., Guo, X. & Chen, J. Targeting the STAT3 pathway with STAT3 degraders. Trends Pharmacol. Sci. 45, 811\u2013823 (2024).","journal-title":"Trends Pharmacol. Sci."},{"key":"2606_CR202","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42233-2","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Expanding PROTACtable genome universe of E3 ligases. Nat. Commun. 14, 6509 (2023).","journal-title":"Nat. Commun."},{"key":"2606_CR203","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13045-025-01703-4","volume":"18","author":"MAA Mamun","year":"2025","unstructured":"Mamun, M. A. A., Bakunts, A. G. & Chernorudskiy, A. L. Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs. J. Hematol. Oncol. 18, 52 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"2606_CR204","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","volume":"9","author":"G Zhong","year":"2024","unstructured":"Zhong, G., Chang, X., Xie, W. & Zhou, X. Targeted protein degradation: advances in drug discovery and clinical practice. Signal Transduct. Target. Ther. 9, 308 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2606_CR205","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","volume":"25","author":"N Zaidi","year":"2025","unstructured":"Zaidi, N., Jaffee, E. M. & Yarchoan, M. Recent advances in therapeutic cancer vaccines. Nat. Rev. Cancer 25, 517\u2013533 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"2606_CR206","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41423-025-01316-4","volume":"22","author":"K Peng","year":"2025","unstructured":"Peng, K., Zhao, X., Fu, Y.-X. & Liang, Y. Eliciting antitumor immunity via therapeutic cancer vaccines. Cell. Mol. Immunol. 22, 840\u2013868 (2025).","journal-title":"Cell. Mol. Immunol."},{"key":"2606_CR207","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41435-025-00365-z","volume":"26","author":"L Tejaswi","year":"2025","unstructured":"Tejaswi, L., Ramesh, P., Aditya, S., Raju, R. & Prasad, T. S. K. Computational neoantigen prediction for cancer immunotherapy. Genes Immun. 26, 531\u2013538 (2025).","journal-title":"Genes Immun."},{"key":"2606_CR208","doi-asserted-by":"publisher","first-page":"109930","DOI":"10.1016\/j.clim.2024.109930","volume":"261","author":"I Baydemir","year":"2024","unstructured":"Baydemir, I., Dulfer, E. A., Netea, M. G. & Dom\u00ednguez-Andr\u00e9s, J. Trained immunity-inducing vaccines: harnessing innate memory for vaccine design and delivery. Clin. Immunol. 261, 109930 (2024).","journal-title":"Clin. Immunol."},{"key":"2606_CR209","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12929-024-01082-x","volume":"31","author":"W-Y Chi","year":"2024","unstructured":"Chi, W.-Y. et al. Molecular targets and strategies in the development of nucleic acid cancer vaccines: from shared to personalized antigens. J. Biomed. Sci. 31, 94 (2024).","journal-title":"J. Biomed. Sci."},{"key":"2606_CR210","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","volume":"23","author":"CL Lorentzen","year":"2022","unstructured":"Lorentzen, C. L., Haanen, J. B., Met, \u00d6 & Svane, I. M. Clinical advances and ongoing trials of mRNA vaccines for cancer treatment. Lancet Oncol. 23, e450\u2013e458 (2022).","journal-title":"Lancet Oncol."},{"key":"2606_CR211","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"2606_CR212","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s43556-024-00241-8","volume":"6","author":"W Lei","year":"2025","unstructured":"Lei, W., Zhou, K., Lei, Y., Li, Q. & Zhu, H. Cancer vaccines: platforms and current progress. Mol. Biomed. 6, 3 (2025).","journal-title":"Mol. Biomed."},{"key":"2606_CR213","first-page":"195","volume":"41","author":"A Conforti","year":"2022","unstructured":"Conforti, A. et al. Linear DNA amplicons as a novel cancer vaccine strategy. J. Exp. Clin. Cancer Res. CR 41, 195 (2022).","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"2606_CR214","first-page":"2004","volume":"40","author":"DA Reardon","year":"2022","unstructured":"Reardon, D. A. et al. Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma. J. Clin. Oncol. 40, 2004\u20132004 (2022).","journal-title":"Clin. Oncol."},{"key":"2606_CR215","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","volume":"131","author":"MP Velasquez","year":"2018","unstructured":"Velasquez, M. P., Bonifant, C. L. & Gottschalk, S. Redirecting T cells to hematological malignancies with bispecific antibodies. Blood 131, 30\u201338 (2018).","journal-title":"Blood"},{"key":"2606_CR216","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.it.2019.01.008","volume":"40","author":"B Blanco","year":"2019","unstructured":"Blanco, B., Compte, M., Lykkemark, S., Sanz, L. & Alvarez-Vallina, L. T-cell-redirecting strategies to \u2018STAb\u2019 tumors: beyond CARs and bispecific antibodies. Trends Immunol. 40, 243\u2013257 (2019).","journal-title":"Trends Immunol."},{"key":"2606_CR217","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/s41401-024-01279-8","volume":"45","author":"H Zong","year":"2024","unstructured":"Zong, H. et al. A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer. Acta Pharmacol. Sin. 45, 1727\u20131739 (2024).","journal-title":"Acta Pharmacol. Sin."},{"key":"2606_CR218","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1158\/0008-5472.CAN-15-2833","volume":"76","author":"SL Moores","year":"2016","unstructured":"Moores, S. L. et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor\u2013resistant lung tumors. Cancer Res. 76, 3942\u20133953 (2016).","journal-title":"Cancer Res."},{"key":"2606_CR219","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.ccell.2024.08.007","volume":"42","author":"K Wang","year":"2024","unstructured":"Wang, K. et al. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells. Cancer Cell 42, 1582\u20131597.e10 (2024).","journal-title":"Cancer Cell"},{"key":"2606_CR220","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41571-024-00966-z","volume":"22","author":"NYL Ngoi","year":"2025","unstructured":"Ngoi, N. Y. L. et al. Synthetic lethal strategies for the development of cancer therapeutics. Nat. Rev. Clin. Oncol. 22, 46\u201364 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2606_CR221","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0800-6","volume":"17","author":"H-Y Tan","year":"2018","unstructured":"Tan, H.-Y. et al. Targeting tumor microenvironment by tyrosine kinase inhibitor. Mol. Cancer 17, 43 (2018).","journal-title":"Mol. Cancer"},{"key":"2606_CR222","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/S1359-6446(05)03666-4","volume":"10","author":"AP Russ","year":"2005","unstructured":"Russ, A. P. & Lampel, S. The druggable genome: an update. Drug Discov. Today 10, 1607\u20131610 (2005).","journal-title":"Drug Discov. Today"},{"key":"2606_CR223","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cbpa.2009.08.003","volume":"13","author":"SJ Dixon","year":"2009","unstructured":"Dixon, S. J. & Stockwell, B. R. Identifying druggable disease-modifying gene products. Curr. Opin. Chem. Biol. 13, 549\u2013555 (2009).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"2606_CR224","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrd.2018.14","volume":"17","author":"TI Oprea","year":"2018","unstructured":"Oprea, T. I. et al. Unexplored therapeutic opportunities in the human genome. Nat. Rev. Drug Discov. 17, 317\u2013332 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR225","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrd.2017.111","volume":"16","author":"JG Moffat","year":"2017","unstructured":"Moffat, J. G., Vincent, F., Lee, J. A., Eder, J. & Prunotto, M. Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nat. Rev. Drug Discov. 16, 531\u2013543 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR226","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.tips.2009.11.002","volume":"31","author":"JNY Chan","year":"2010","unstructured":"Chan, J. N. Y., Nislow, C. & Emili, A. Recent advances and method development for drug target identification. Trends Pharmacol. Sci. 31, 82\u201388 (2010).","journal-title":"Trends Pharmacol. Sci."},{"key":"2606_CR227","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.3390\/cancers15174352","volume":"15","author":"J Jin","year":"2023","unstructured":"Jin, J., Yoshimura, K., Sewastjanow-Silva, M., Song, S. & Ajani, J. A. Challenges and prospects of patient-derived xenografts for cancer research. Cancers 15, 4352 (2023).","journal-title":"Cancers"},{"key":"2606_CR228","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.amjmed.2023.03.033","volume":"136","author":"EY Adashi","year":"2023","unstructured":"Adashi, E. Y., O\u2019Mahony, D. P. & Cohen, I. G. The FDA modernization act 2.0: drug testing in animals is rendered optional. Am. J. Med. 136, 853\u2013854 (2023).","journal-title":"Am. J. Med."},{"key":"2606_CR229","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun, D., Gao, W., Hu, H. & Zhou, S. Why 90% of clinical drug development fails and how to improve it?. Acta Pharm. Sin. B 12, 3049\u20133062 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"2606_CR230","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3390\/cells10030659","volume":"10","author":"HYK Yip","year":"2021","unstructured":"Yip, H. Y. K. & Papa, A. Signaling pathways in cancer: therapeutic targets, combinatorial treatments, and new developments. Cells 10, 659 (2021).","journal-title":"Cells"},{"key":"2606_CR231","doi-asserted-by":"crossref","unstructured":"Proietto, M. et al. Tumor heterogeneity: preclinical models, emerging technologies, and future applications. Front. Oncol. 13, 1164535 (2023).","DOI":"10.3389\/fonc.2023.1164535"},{"key":"2606_CR232","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1470-2045(24)00040-8","volume":"25","author":"BHL Goulart","year":"2024","unstructured":"Goulart, B. H. L. et al. Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small cell lung cancer: an FDA pooled analysis. Lancet Oncol. 25, 455\u2013462 (2024).","journal-title":"Lancet Oncol."},{"key":"2606_CR233","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.7150\/jca.32205","volume":"10","author":"LM Hess","year":"2019","unstructured":"Hess, L. M., Brnabic, A., Mason, O., Lee, P. & Barker, S. Relationship between progression-free survival and overall survival in randomized clinical trials of targeted and biologic agents in oncology. J. Cancer 10, 3717\u20133727 (2019).","journal-title":"J. Cancer"},{"key":"2606_CR234","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/j.ccell.2024.09.005","volume":"42","author":"X Mao","year":"2024","unstructured":"Mao, X., Alexander, G. C. & Li, G. Accelerated approvals: early-phase success or premature authorization?. Cancer Cell 42, 1799\u20131802 (2024).","journal-title":"Cancer Cell"},{"key":"2606_CR235","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41586-022-04437-2","volume":"603","author":"P Jaaks","year":"2022","unstructured":"Jaaks, P. et al. Effective drug combinations in breast, colon and pancreatic cancer cells. Nature 603, 166\u2013173 (2022).","journal-title":"Nature"},{"key":"2606_CR236","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/ijc.34181","volume":"152","author":"A Haslam","year":"2023","unstructured":"Haslam, A., Olivier, T., Powell, K., Tuia, J. & Prasad, V. Eventual success rate and predictors of success for oncology drugs tested in phase I trials. Int. J. Cancer 152, 276\u2013282 (2023).","journal-title":"Int. J. Cancer"},{"key":"2606_CR237","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.3390\/cancers12082313","volume":"12","author":"CA Uyl-de Groot","year":"2020","unstructured":"Uyl-de Groot, C. A., Heine, R., Krol, M. & Verweij, J. Unequal access to newly registered cancer drugs leads to potential loss of life-years in Europe. Cancers 12, 2313 (2020).","journal-title":"Cancers"},{"key":"2606_CR238","doi-asserted-by":"publisher","first-page":"e2216191","DOI":"10.1001\/jamanetworkopen.2022.16191","volume":"5","author":"K Jenei","year":"2022","unstructured":"Jenei, K. The timing of cancer drug approvals in the United States and Europe. JAMA Netw. Open 5, e2216191 (2022).","journal-title":"JAMA Netw. Open"},{"key":"2606_CR239","first-page":"101483","volume":"55","author":"X Mao","year":"2025","unstructured":"Mao, X. et al. Regulatory flexibilities balancing unmet needs, benefits and risks in the approvals of imported cancer drugs in China: a cohort study from 2012 to 2021. Lancet Reg. Health West. Pac. 55, 101483 (2025).","journal-title":"Lancet Reg. Health West. Pac."},{"key":"2606_CR240","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1377\/hlthaff.2024.00089","volume":"43","author":"OJ Wouters","year":"2024","unstructured":"Wouters, O. J. & Kuha, J. Low- and middle-income countries experienced delays accessing new essential medicines, 1982-2024. Health Aff. Proj. Hope 43, 1410\u20131419 (2024).","journal-title":"Health Aff. Proj. Hope"},{"key":"2606_CR241","doi-asserted-by":"publisher","first-page":"m4087","DOI":"10.1136\/bmj.m4087","volume":"371","author":"TP Hanna","year":"2020","unstructured":"Hanna, T. P. et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ 371, m4087 (2020).","journal-title":"BMJ"},{"key":"2606_CR242","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46736-1","volume":"9","author":"Y Li","year":"2019","unstructured":"Li, Y. et al. The influence on survival of delay in the treatment initiation of screening detected nonsymptomatic breast cancer. Sci. Rep. 9, 10158 (2019).","journal-title":"Sci. Rep."},{"key":"2606_CR243","doi-asserted-by":"crossref","unstructured":"Khadem Broojerdi, A. et al. The World Health Organization global benchmarking tool an instrument to strengthen medical products regulation and promote universal health coverage. Front. Med. 7, 457 (2020).","DOI":"10.3389\/fmed.2020.00457"},{"key":"2606_CR244","unstructured":"WHO. List of National Regulatory Authorities (NRAs) operating at maturity level 3 (ML3) and maturity level 4 (ML4). https:\/\/www.who.int\/publications\/m\/item\/list-of-nras-operating-at-ml3-and-ml4 (2024)."},{"key":"2606_CR245","unstructured":"WHO. Global Benchmarking Tools. https:\/\/www.who.int\/tools\/global-benchmarking-tools (2025)."},{"key":"2606_CR246","doi-asserted-by":"crossref","unstructured":"WHO. WHO collaborative registration procedure using stringent regulatory authorities\u2019 medicine evaluation: reliance in action? https:\/\/www.who.int\/news\/item\/15-02-2022-who-collaborative-registration-procedure-using-stringent-regulatory-authorities-medicine-evaluation-reliance-in-action (2022).","DOI":"10.1080\/17512433.2022.2037419"},{"key":"2606_CR247","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4103\/2229-3485.71851","volume":"1","author":"H Wileman","year":"2010","unstructured":"Wileman, H. & Mishra, A. Drug lag and key regulatory barriers in the emerging markets. Perspect. Clin. Res. 1, 51\u201356 (2010).","journal-title":"Perspect. Clin. Res."},{"key":"2606_CR248","doi-asserted-by":"publisher","first-page":"104295","DOI":"10.1016\/j.drudis.2025.104295","volume":"30","author":"P Franco","year":"2025","unstructured":"Franco, P. & Haefliger, S. Competition of regulatory ecosystems in approving medicines: policy implications in the case of Europe. Drug Discov. Today 30, 104295 (2025).","journal-title":"Drug Discov. Today"},{"key":"2606_CR249","first-page":"10","volume":"7","author":"WY Hwang","year":"2023","unstructured":"Hwang, W. Y. et al. Challenges in global access to CAR-T cells: an Asian perspective. Blood Cell Ther. 7, 10\u201313 (2023).","journal-title":"Blood Cell Ther."},{"key":"2606_CR250","doi-asserted-by":"publisher","first-page":"S373","DOI":"10.1016\/j.jtct.2023.12.523","volume":"30","author":"R Atallah","year":"2024","unstructured":"Atallah, R. et al. The GLAMM1 study - global access to myeloma medications: potential barriers to chimeric antigen receptors (CART) and T-cell-engaging bispecific antibodies (TCE) globally. Transplant. Cell. Ther. 30, S373\u2013S374 (2024).","journal-title":"Transplant. Cell. Ther."},{"key":"2606_CR251","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.drudis.2018.01.039","volume":"23","author":"H Chen","year":"2018","unstructured":"Chen, H., Engkvist, O., Wang, Y., Olivecrona, M. & Blaschke, T. The rise of deep learning in drug discovery. Drug Discov. Today 23, 1241\u20131250 (2018).","journal-title":"Drug Discov. Today"},{"key":"2606_CR252","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.tips.2023.06.010","volume":"44","author":"FW Pun","year":"2023","unstructured":"Pun, F. W., Ozerov, I. V. & Zhavoronkov, A. AI-powered therapeutic target discovery. Trends Pharmacol. Sci. 44, 561\u2013572 (2023).","journal-title":"Trends Pharmacol. Sci."},{"key":"2606_CR253","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/d41573-022-00025-1","volume":"21","author":"MKP Jayatunga","year":"2022","unstructured":"Jayatunga, M. K. P., Xie, W., Ruder, L., Schulze, U. & Meier, C. AI in small-molecule drug discovery: a coming wave?. Nat. Rev. Drug Discov. 21, 175\u2013176 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2606_CR254","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493\u2013500 (2024).","journal-title":"Nature"},{"key":"2606_CR255","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg7865","volume":"9","author":"V Chenthamarakshan","year":"2023","unstructured":"Chenthamarakshan, V. et al. Accelerating drug target inhibitor discovery with a deep generative foundation model. Sci. Adv. 9, eadg7865 (2023).","journal-title":"Sci. Adv."},{"key":"2606_CR256","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1166","volume":"9","author":"C Finan","year":"2017","unstructured":"Finan, C. et al. The druggable genome and support for target identification and validation in drug development. Sci. Transl. Med. 9, eaag1166 (2017).","journal-title":"Sci. Transl. Med."},{"key":"2606_CR257","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s42256-021-00325-y","volume":"3","author":"R Schulte-Sasse","year":"2021","unstructured":"Schulte-Sasse, R., Budach, S., Hnisz, D. & Marsico, A. Integration of multiomics data with graph convolutional networks to identify new cancer genes and their associated molecular mechanisms. Nat. Mach. Intell. 3, 513\u2013526 (2021).","journal-title":"Nat. Mach. Intell."},{"key":"2606_CR258","unstructured":"Insilico medicine. PandaOmics. https:\/\/pharma.ai\/pandaomics (2025)."},{"key":"2606_CR259","unstructured":"BenevolentAI. AI Drug Discovery. AI Pharma. https:\/\/www.benevolent.com\/ (2025)."},{"key":"2606_CR260","doi-asserted-by":"publisher","first-page":"bbac409","DOI":"10.1093\/bib\/bbac409","volume":"23","author":"R Luo","year":"2022","unstructured":"Luo, R. et al. BioGPT: generative pretrained transformer for biomedical text generation and mining. Brief. Bioinform. 23, bbac409 (2022).","journal-title":"Brief. Bioinform."},{"key":"2606_CR261","unstructured":"Insilico medicine. ChatPandaGPT. https:\/\/insilico.com\/pandaomics\/help\/chatpandagpt (2025)."},{"key":"2606_CR262","unstructured":"Insilico medicine. Insilico Medicine announces positive topline results of ISM001-055 for the treatment of idiopathic pulmonary fibrosis (IPF) developed using generative AI. https:\/\/insilico.com\/news\/tnik-ipf-phase2a (2024)."},{"key":"2606_CR263","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/s41587-024-02357-2","volume":"42","author":"M Senior","year":"2024","unstructured":"Senior, M. Biotech financing: darkest before the dawn. Nat. Biotechnol. 42, 1331\u20131338 (2024).","journal-title":"Nat. Biotechnol."},{"key":"2606_CR264","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s43018-024-00857-3","volume":"5","author":"M Senior","year":"2024","unstructured":"Senior, M. Beyond the hype of AI in cancer R&D. Nat. Cancer 5, 1759\u20131761 (2024).","journal-title":"Nat. Cancer"},{"key":"2606_CR265","unstructured":"China Med Device. Guideline on Artificial Intelligence Medical Devices. https:\/\/chinameddevice.com\/guideline-on-artificial-intelligence-medical-devices\/ (2022)."},{"key":"2606_CR266","unstructured":"FDA. Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological (2025)."},{"key":"2606_CR267","unstructured":"Safetydrugs. Artificial Intelligence and EMA: initiatives for use in pharmacovigilance. https:\/\/safetydrugs.it\/en\/artificial-intelligence-and-ema\/ (2024)."},{"key":"2606_CR268","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01735-9","volume":"22","author":"Q Liu","year":"2023","unstructured":"Liu, Q. et al. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. Mol. Cancer 22, 28 (2023).","journal-title":"Mol. Cancer"},{"key":"2606_CR269","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41587-020-0601-5","volume":"39","author":"F Mo","year":"2021","unstructured":"Mo, F. et al. Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat. Biotechnol. 39, 56\u201363 (2021).","journal-title":"Nat. Biotechnol."},{"key":"2606_CR270","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.immuni.2023.09.010","volume":"56","author":"N Singh","year":"2023","unstructured":"Singh, N. & Maus, M. V. Synthetic manipulation of the cancer-immunity cycle: CAR-T-cell therapy. Immunity 56, 2296\u20132310 (2023).","journal-title":"Immunity"},{"key":"2606_CR271","doi-asserted-by":"crossref","unstructured":"Alabi, S. B. & Crews, C. M. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs. J. Biol. Chem. 296, 100647 (2021).","DOI":"10.1016\/j.jbc.2021.100647"},{"key":"2606_CR272","doi-asserted-by":"crossref","unstructured":"Expanding the ligand spaces for E3 ligases for the design of protein degraders. Bioorg. Med. Chem. 105, 117718 (2024).","DOI":"10.1016\/j.bmc.2024.117718"},{"key":"2606_CR273","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3390\/ph16121649","volume":"16","author":"MSW Jamal","year":"2023","unstructured":"Jamal, M. S. W. et al. Revolutionizing drug targeting strategies: integrating artificial intelligence and structure-based methods in PROTAC development. Pharmaceuticals 16, 1649 (2023).","journal-title":"Pharmaceuticals"},{"key":"2606_CR274","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","volume":"25","author":"M Hinterndorfer","year":"2025","unstructured":"Hinterndorfer, M., Spiteri, V. A., Ciulli, A. & Winter, G. E. Targeted protein degradation for cancer therapy. Nat. Rev. Cancer 25, 493\u2013516 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"2606_CR275","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1470-2045(22)00377-1","volume":"23","author":"MP Lythgoe","year":"2022","unstructured":"Lythgoe, M. P. & Sullivan, R. Project Orbis: the UK experience after 1 year. Lancet Oncol. 23, 978\u2013981 (2022).","journal-title":"Lancet Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02606-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02606-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02606-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:02:54Z","timestamp":1778515374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02606-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":275,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2606"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02606-7","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.T.L. is a member of the Scientific Advisory Boards of KSQ, Inc., BioCytics, Zai Laboratories, Appel Sauce Studios, Zola Therapeutics, and the Ludwig Institute. Q.Z. is the editorial board member of Signal Transduction and Targeted Therapy, but he has not been involved in the process of the manuscript handling. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"174"}}